Evidence map›Paper›PMID 31527416›Full record

ArticleJournal of clinical medicine2019

A Novel Ex Vivo System Using 3D Polymer Scaffold to Culture Circulating Tumor Cells from Breast Cancer Patients Exhibits Dynamic E-M Phenotypes.

Tamasa De, Shina Goyal, Gowri Balachander, Kaushik Chatterjee, Prashant Kumar, Govind Babu K, Annapoorni Rangarajan

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 26 citations in OpenAlex.

  1. Biomimetic Scaffold-Based 3D Models for Decoding Cancer Biology and Advancing Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Tamasa DeDepartment of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore 560012, India. tamasade@iisc.ac.in.ORCID 0000-0002-5292-6492
Shina GoyalDepartment of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore 560029, India. shina.goyal@gmail.com.
Gowri BalachanderCenter for Biosystems Science and Engineering, Indian Institute of Science, Bangalore 560012, India. phsgmb@nus.edu.sg.
Kaushik ChatterjeeCenter for Biosystems Science and Engineering, Indian Institute of Science, Bangalore 560012, India. kchatterjee@iisc.ac.in.
Prashant KumarInstitute of Bioinformatics, International Technology Park, Bangalore 560066, India. prashant@ibioinformatics.org.
Govind Babu KDepartment of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore 560029, India. kgblaugh@gmail.com.
Annapoorni RangarajanDepartment of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore 560012, India. anu@iisc.ac.in.
Indian Institute of Science Bangalore · INKidwai Memorial Institute of Oncology · INManipal Academy of Higher Education · INNational University Health System · SG

Funding

Rajiv Gandhi University of Health Science, Bangalore (RGUHS) NO. RGU/ADV.RES/CR/002/2017-18 DATED: 21.12.2017
6 · The paper itself

Abstract

The majority of the cancer-associated deaths is due to metastasis-the spread of tumors to other organs. Circulating tumor cells (CTCs), which are shed from the primary tumor into the circulation, serve as precursors of metastasis. CTCs have now gained much attention as a new prognostic and diagnostic marker, as well as a screening tool for patients with metastatic disease. However, very little is known about the biology of CTCs in cancer metastasis. An increased understanding of CTC biology, their heterogeneity, and interaction with other cells can help towards a better understanding of the metastatic process, as well as identify novel drug targets. Here we present a novel ex vivo 3D system for culturing CTCs from breast cancer patient blood samples using porous poly(ε-caprolactone) (PCL) scaffolds. As a proof of principle study, we show that ex vivo culture of 12/16 (75%) advanced stage breast cancer patient blood samples were enriched for CTCs identified as CK+ (cytokeratin positive) and CD45- (CD45 negative) cells. The deposition of extracellular matrix proteins on the PCL scaffolds permitted cellular attachment to these scaffolds. Detection of Ki-67 and bromodeoxyuridine (BrdU) positive cells revealed proliferating cell population in the 3D scaffolds. The CTCs cultured without prior enrichment exhibited dynamic differences in epithelial (E) and mesenchymal (M) composition. Thus, our 3D PCL scaffold system offers a physiologically relevant model to be used for studying CTC biology as well as for individualized testing of drug susceptibility. Further studies are warranted for longitudinal monitoring of epithelial-mesenchymal transition (EMT) in CTCs for clinical association.

Indexed as

3D culturebreast cancercirculating tumor cells (CTCs)epithelial-mesenchymal heterogeneity

Identifiers

PMID31527416
PMCPMC6780381
OpenAlexW2972414936

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.